PMHS Polomar Health Services, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1265521 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11,701.9%
TTM net income YoY-303.9%
TTM EPS YoY-300.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin49.1%
Operating margin-221.0%
Net margin-224.6%
FCF margin—
EBITDA margin-14.8%
Returns
ROE-469.6%
ROA-193.3%
ROIC (approx.)-392.6%
Asset turnover0.86x
Leverage & solvency
Liabilities / assets325.5%
Debt / equity—
Current ratio0.24x
Interest coverage-61.19x
Cash quality & payout
Operating cash flow / net income-0.04x
Accruals ratio-200.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $648,231 | $58,824 | $41,844 | $34,526 |
| Cost of revenue | $188,132 | $27,921 | $4,294 | — |
| Gross profit | $460,099 | $30,903 | $37,550 | $34,526 |
| SG&A expense | $10.94M | $1.28M | $450,450 | $215,979 |
| Operating income | -$10.55M | -$1.30M | -$440,832 | -$181,453 |
| Interest expense | $150,841 | $41,837 | $495 | — |
| Net income | -$10.70M | -$1.34M | -$587,997 | -$181,124 |
| EBITDA | -$776,936 | -$1.04M | -$434,999 | — |
| EPS (basic) | -0.39 | -0.05 | -0.02 | 0.00 |
| EPS (diluted) | -0.39 | -0.05 | -0.02 | 0.00 |
| Weighted avg. shares (diluted) | 27.76M | 27.66M | 26.12M | — |
| Balance sheet | ||||
| Cash & equivalents | $132,150 | $6,191 | $8,808 | $225,619 |
| Receivables | — | — | — | $30,000 |
| Inventory | $93,636 | $68,777 | $3,459 | — |
| Current assets | $322,727 | $76,813 | $12,267 | $261,484 |
| PP&E, net | $43,452 | $81,405 | — | — |
| Total assets | $390,043 | $9.95M | $107,099 | $261,484 |
| Current liabilities | $1.61M | $1.34M | $102,455 | $74,715 |
| Short-term debt | — | — | $32,484 | — |
| Total liabilities | $1.61M | $1.35M | $151,635 | $74,715 |
| Shareholders' equity | -$1.97M | $8.60M | -$44,536 | $186,769 |
| Shares outstanding | 28.02M | 27.66M | 27.66M | 107.58M |
| Cash flow statement | ||||
| Operating cash flow | -$395,995 | -$1.02M | -$534,307 | -$40,934 |
| Capital expenditure | — | $90,893 | — | — |
| Free cash flow | — | -$1.11M | — | — |
| Investing cash flow | — | -$90,893 | — | — |
| Financing cash flow | $521,954 | $1.11M | $317,496 | $266,553 |
| Depreciation & amortization | $9.77M | $263,280 | $5,833 | — |
| Stock-based compensation | $129,645 | — | — | $173,995 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.